Pfizer CEO Albert Bourla: Seagen will bring in $10 billion in revenues by 2030
October 31, 2023 at 03:44 pm
Share
Pfizer (PFE) Chairman and CEO Albert Bourla discusses the $43 billion acquisition of cancer biotech company Seagen Inc. (SGEN), for which U.S. approval is still pending. The integration of Seagen will require additional investment, but is expected to generate $10 billion in revenues by 2030. Finally, despite the recent wave of consolidation in the sector, he anticipates few major mergers and acquisitions in 2024.
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).